---
title: 'Software Daily Summary: What Happened on November 3, 2026'
headline: Open Targets’ Mira pipeline adds clinical evidence, with gaps in mapping
description: The September release included 289,954 reports, but fewer than half contribute
  to target-disease evidence.
url: https://thebench.bio/news/software/2026-11-03
topic: software
date: '2026-11-03'
covers:
- '2026-11-03'
date_published: '2026-11-03T12:02:54Z'
date_modified: '2026-11-03T12:02:54Z'
tags:
- Software
sources: 1
publisher: TheBench.Bio
---

# Software Daily Summary: What Happened on November 3, 2026

**Open Targets’ Mira pipeline adds clinical evidence, with gaps in mapping**

The September release included 289,954 reports, but fewer than half contribute to target-disease evidence.

## Today in brief

Open Targets’ Mira pipeline integrated evidence from 23 sources and supplied 289,954 reports for its September 2026 platform release. [1] The update shifted some drugs from Phase III to Approval and changed evidence scores across target-disease pairs. [1]

## Mira’s clinical evidence varies in coverage by development stage

Mira brings together clinical reports from 23 sources, standardizes drug and disease identifiers, and assigns reports to 13 shared clinical stages. [1] The pipeline supplied 289,954 reports for the September 2026 release, compared with 285,213 around the March release. [1]

The September Clinical Precedence dataset drew on 117,152 reports, including 94,480 clinical-trial reports, and covered 11,418 drug-disease pairs in the platform’s Indications widget. [1] Open Targets estimates that roughly one-third of drugs previously listed at Phase III moved to Approval, largely because newer regulatory labels were available. [1]

At Approval, 55% of indications had at least two supporting reports and 41% had three or more. Phase I evidence mostly relied on one report. [1] More than 90% of Approval-stage reports were fully mapped, compared with 55% at Phase I and under 10% at Preclinical. [1]

Of 47,870 target-disease pairs compared between releases, more than 9,500 early-development pairs gained evidence score, with an average increase of 0.323. [1] Around 3,200 pairs in a late-clinical score band lost an average of 0.5. One example was CTLA4-cutaneous melanoma, whose score fell from 0.7 to 0.2 after two ipilimumab trials were mapped to broader melanoma. [1]

Open Targets says more than 290,000 reports meet Mira’s inclusion criteria, but mapping limitations mean fewer than half contribute to target-disease evidence. [1] In June, the team added a large language model framework to extract study purpose, drugs, and indications from ClinicalTrials.gov records. The authors reported more drug-indication pairs and fewer false associations against a manually annotated benchmark. [1]

## The day in numbers

- **23**: Sources integrated by Mira. [1]
- **289,954**: Clinical reports supplied to the September 2026 release. [1]
- **11,418**: Drug-disease pairs in the September release’s Indications widget. [1]

## Also published

- [The Shelf Life of LLM findings](<https://blog.stephenturner.us/p/llm-claims-shelf-life>), Paired Ends
- [Cambridge Cheminformatics Network meeting](<https://macinchem.org/2026/11/03/cambridge-cheminformatics-network-meeting-5/>), Mac in Chem
- [AI: an early warning system for patient safety](<https://pharmafile.com/features/ai-an-early-warning-system-for-patient-safety/>), Pharmafile
- [ChemDraft an open-source chemical drawing package](<https://macinchem.org/2026/11/03/chemdraft-and-open-source-chemical-drawing-package/>), Mac in Chem

## Sources

1. [Introducing Open Targets Mira: A Pipeline to Enhance Clinical Trial Evidence in the Open Targets Platform](<https://blog.opentargets.org/introducing-open-targets-mira/>), Open Targets, 2026-11-03

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://blog.opentargets.org/introducing-open-targets-mira/>